SLC7A11 and cancer: The aberrant regulation of key factors involved in ferroptosis and their regulators is closely linked to cancer progression, and targeting the ferroptosis network, particularly GPX4 and SLC7A11, may offer new therapeutic options for cancer and other diseases [48,49].